UK markets closed
NIKKEI 225
38,102.44 -712.12 (-1.83%) HANG SENG
17,936.12 -5.66 (-0.03%) CRUDE OIL
80.54 +0.21 (+0.26%) GOLD FUTURES
2,335.00 +6.00 (+0.26%) DOW
38,778.10 +188.94 (+0.49%) Bitcoin GBP
52,451.47 -164.61 (-0.31%)
Nektar Therapeutics (ITH.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 08:08AM CEST
| Previous close | 1.1340 |
| Open | 1.0750 |
| Bid | 1.0640 x 50000 |
| Ask | 1.0880 x 50000 |
| Day's range | 1.0750 - 1.0750 |
| 52-week range | 0.3901 - 1.6870 |
| Volume | |
| Avg. volume | 841 |
| Market cap | 197.822M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of a poster highlighting new preclinical data on NKTR-0165 at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress.
- PR Newswire
Nektar Management to Present at Upcoming Investor Conferences
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:
- PR Newswire
Nektar Therapeutics Reports First Quarter 2024 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024.
© 2024 Yahoo. All rights reserved.